MANKIND2,246.00

Mankind Pharma Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLATORNTPHARMLAURUSLABSBIOCONALKEMLUPINGLENMARKMcap ₹92,715 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt207.28,511.56,311.56,311.5
Net Debt-2,432.96,413.34,382.54,382.5
Total Debt/Equity0.020.580.380.38
Net Debt/Equity-0.250.440.260.26
Total Debt/EBITDA0.082.821.741.74
Net Debt/EBITDA-0.962.131.211.15
Interest Coverage (EBIT/Interest)63.735.584.274.27
Total Debt/Total Capital %2.1236.8827.5927.59
As Filed — company-reported covenants
Debt/Equity (as filed)0.590.390.25
Debt Service Coverage (as filed)0.600.470.59
Interest Service Coverage (as filed)130.554.098.61
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.